Genetic Technologies Limited (NASDAQGENE – Get Rating) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.61 and traded as high as $1.65. Genetic Technologies shares last traded at $1.63, with a volume of 26,219 shares trading hands. Genetic Technologies Stock Down 1.5 % […]

In the vast oceans, one would assume their inhabitants can travel far and wide and, as a result, populations of a species would mix freely. But this doesn't appear to be the case for a vital forage fish called the sand lance.

Genetic Technologies (NASDAQGENE) Stock Passes Above 200 Day Moving Average of $1.24

ARS Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company that specializes in developing and commercializing innovative treatments for rare genetic disorders. The company's flagship product, Rylutek, is an oral formulation of treprostinone used to treat congenital adrenal hyperplasia (CAH), a rare genetic disorder that affects the production of hormones in the adrenal glands.On February 20th, Leerink Partners issued a research report on ARS Pharmaceuticals, Inc., forecasting the company's earnings per share for FY2025 to be $0.75. This represents a decrease from their previous estimate of $1.00 per share.Leerink Partners analyst R. Ruiz cited several factors that contributed to this revision in his research report, including increased competition in the CAH market and potential delays in the development of new products. The analyst also noted that the company's recent acquisition of a smaller competitor, Novexpert, may have impacted its ability to generate revenue from new product launches.Despite these challenges, ARS Pharmaceuticals, Inc. remains committed to advancing its pipeline of treatments for rare genetic disorders and expanding its presence in the global market. The company has a strong track record of innovation and has successfully launched several products in recent years, including Rylutek and its oral formulation of megestrol acetate (Megace).Overall, while Leerink Partners' revised earnings forecast for FY2025 may be concerning to investors, it is important to note that the company has a strong track record of innovation and a robust pipeline of products in development. As such, investors should continue to monitor the company's progress closely and consider its long-term potential as a leader in the rare genetic disorders market.

Applied Genetic Technologies’ (AGTC) “Outperform” Rating Reaffirmed at Wedbush

Applied Genetic Technologies (NASDAQAGTC) Coverage Initiated by Analysts at StockNews.com

Stifel Nicolaus Cuts Applied Genetic Technologies (NASDAQAGTC) Price Target to $3.00

Western-developed technique irons out brain wrinkles for accurate insight on brain disorders

(marketscreener.com) PHILADELPHIA, Nov. 08, 2022 -- Passage Bio, Inc. , a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that William Chou, M.D., chief executive officer, will participate in a fireside chat at the Guggenheim 4th Annual Immunology & Neurology Day on...https//www.marketscreener.com/quote/stock/PASSAGE-BIO-INC-103658170/news/Passage-Bio-to-Present-at-Guggenheim-4th-Annual-Immunology-Neurology-Day-42240252/?utm_medium=RSS&utm_content=20221108

"I have to be thin," "Eternally starved," "I want to be perfect." These are the names of accounts Instagram's algorithms promoted to an account registered as belonging to a 13-year-old girl who expressed interest in weight loss and dieting.

Genetic highlights study suggesting geneType test's superiority in detecting breast cancer risk

Scientists discover California condors can give birth without any male genetic DNA.

Researchers have identified genetic factors that stop tusk development.

Companies investigate how therapies including Crispr might treat a debilitating genetic disease

Researchers urge caution on genetic studies early in outbreaks.

Applied Genetic Technologies (NASDAQAGTC) Given New $16.00 Price Target at HC Wainwright

Apogee Therapeutics is a biopharmaceutical company that specializes in developing and commercializing novel therapies for rare genetic disorders. The company's lead product candidate is APG-103, an oral therapy for the treatment of phenylketonuria (PKU), a rare genetic disorder that affects the metabolism of amino acids.On August 24, 2022, Apogee Therapeutics announced that its stock price had reached a new 52-week high of $38.34 on the NASDAQ Global Select Market. This represents an increase of over 160% from the company's 52-week low of $14.79, which was reached on March 15, 2022.The stock price increase can be attributed to several factors, including positive news about APG-103's clinical trial results and regulatory progress, as well as increasing investor interest in the rare disease market. In addition, Apogee Therapeutics has recently announced plans to expand its operations and develop new therapies for other rare genetic disorders.Overall, the stock price increase reflects investors' confidence in the company's ability to successfully bring APG-103 to market and generate revenue from its commercialization.

New research finds that TikTok's powerful algorithms are promoting videos about self-harm and eating disorders to teens

Wells Fargo & Company Downgrades Applied Genetic Technologies (NASDAQAGTC) to Equal Weight

Researchers detect genetic changes in response to seasonal change.

Applied Genetic Technologies’ (AGTC) “Outperform” Rating Reaffirmed at Wedbush

With CRISPR-Cas9 technology, humans can now rapidly change the evolutionary course of animals or plants by inserting genes that can easily spread through entire populations. Evolutionary geneticist Asher Cutter proposes that we call this evolutionary meddling "genetic welding." In an opinion paper published March 28 in the journal Trends in Genetics, he argues that we must scientifically and ethically scrutinize the potential consequences of genetic welding before we put it into practice.

Future swarms could face decoy pheromones, genetic manipulation, blocking chemicals.

Genetic analysis confirms bear linked to previous attack on father and son

It’s not a panacea for gastrointestinal disorders, but it eases some patients’ symptoms

Head-To-Head Analysis Applied Genetic Technologies (NASDAQAGTC) vs. VectivBio (NASDAQVECT)

They won the genetic and also financial lottery just by being born.

As a teenager, my sexuality was used to write off my anorexia as something one doctor told me I would ‘grow out of’ when I came to terms with being gay

The struggles of Ashlee Thomas and Anastasia Vlasova illustrate Instagram's potential "toxic" effect on teen girls, as highlighted in the congressional testimony Tuesday of Facebook whistleblower Frances Haugen.

Stanford professor saw urgent need to treat insomnia, apnea and other disorders

Genetic analysis confirms bear linked to previous attack on father and son

Stifel Nicolaus Cuts Applied Genetic Technologies (NASDAQAGTC) Price Target to $3.00

Wells Fargo & Company Downgrades Applied Genetic Technologies (NASDAQAGTC) to Equal Weight

Third-party tools grab personal information from medical, genetic-testing company sites.

Genetic analysis confirms bear linked to previous attack on father and son

PTC Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes therapies for rare genetic disorders. The company's lead product candidate is Translarna, an oral therapy for Duchenne muscular dystrophy (DMD), which has been granted orphan drug designation in the United States and Europe.On August 10, 2021, Deutsche Bank AG announced that it had purchased approximately 5.3 million shares of PTC Therapeutics, Inc.'s common stock for a total purchase price of $47.9 million. This represents a significant investment in the company and its ongoing development efforts.PTC Therapeutics, Inc. has been working to advance Translarna through clinical trials and regulatory approvals. The company has reported positive results from several studies, including a Phase 3 trial that demonstrated statistically significant improvements in motor function and quality of life measures compared to placebo in patients with DMD.In addition to Translarna, PTC Therapeutics, Inc. is also developing other therapies for rare genetic disorders, including an oral therapy for cystic fibrosis and a gene therapy for spinal muscular atrophy. The company has a strong pipeline of potential therapies in various stages of development, which could provide significant growth opportunities in the future.Overall, Deutsche Bank AG's investment in PTC Therapeutics, Inc.'s shares reflects the company's confidence in the potential of Translarna and its other therapies to address unmet medical needs for patients with rare genetic disorders.

TikTok’s algorithms are promoting videos about self-harm and eating disorders to vulnerable teens, according to a report published Wednesday that…

Plus My wife says her family has eating disorders. I'm starting to think they're sociopaths.

Twist, Illumina in partnership to expand access to genetic sequencing panel

With CRISPR-Cas9 technology, humans can now rapidly change the evolutionary course of animals or plants by inserting genes that can easily spread through entire populations. Evolutionary geneticist Asher Cutter proposes that we call this evolutionary meddling "genetic welding." In an opinion paper published March 28 in the journal Trends in Genetics, he argues that we must scientifically and ethically scrutinize the potential consequences of genetic welding before we put it into practice.

Genetic tagging offers insight into the secret lives of basking sharks.

With CRISPR-Cas9 technology, humans can now rapidly change the evolutionary course of animals or plants by inserting genes that can easily spread through entire populations. Evolutionary geneticist Asher Cutter proposes that we call this evolutionary meddling "genetic welding." In an opinion paper published March 28 in the journal Trends in Genetics, he argues that we must scientifically and ethically scrutinize the potential consequences of genetic welding before we put it into practice.

A new study performed by researchers at the University of Utah Health suggests that a rare genetic mutation may help explain why some families are more likely to have diabetes and kidney failure. They believe the finding, made within multiple generations of a single family, could lead to better treatments for these disorders in a […]The post New Study Discovers Why Some Families Run The Risk Of Diabetes, Kidney Failure appeared first on Revyuh.

A deep look into the genetic damage left by the disaster.

Edinburgh University researchers have identified hundreds of genetic variants - differences in people's genetic make-up - linked with liking specific foods.

Genetic Technologies (NASDAQGENE) Stock Passes Above 200 Day Moving Average of $1.24

With CRISPR-Cas9 technology, humans can now rapidly change the evolutionary course of animals or plants by inserting genes that can easily spread through entire populations. Evolutionary geneticist Asher Cutter proposes that we call this evolutionary meddling "genetic welding." In an opinion paper published March 28 in the journal Trends in Genetics, he argues that we must scientifically and ethically scrutinize the potential consequences of genetic welding before we put it into practice.

Genetic analysis confirms bear linked to previous attack on father and son

With CRISPR-Cas9 technology, humans can now rapidly change the evolutionary course of animals or plants by inserting genes that can easily spread through entire populations. Evolutionary geneticist Asher Cutter proposes that we call this evolutionary meddling "genetic welding." In an opinion paper published March 28 in the journal Trends in Genetics, he argues that we must scientifically and ethically scrutinize the potential consequences of genetic welding before we put it into practice.

Genetic analysis confirms bear linked to previous attack on father and son